Search Results
Results found for "Design Pharmaceuticals"
- 📰 GPCR Weekly News, January 16 to 22, 2023
amended deal with Gilead on anti-CCR8 antibody InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical
- 📰 GPCR Weekly News, June 5 to 11, 2023
GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Industry News X4 Pharmaceuticals
- 📰 GPCR Weekly News, August 14 to 20, 2023
immunotherapy drug Trevena Reports Second Quarter 2023 Results and Provides Business Update Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, September 11 to 17, 2023
Research Associate NEW Research Technician Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, September 4 to 10, 2023
| Chemotactic Cytokines GPCR Jobs NEW Senior Research Associate, In Vitro Pharmacology - Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, May 8 to 14, 2023
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage X4 Pharmaceuticals
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
results for metabolic disorders INDIGO Biosciences, INC as a Preferred Supplier at Prendio Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, April 22 to 28, 2024
great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals
- 📰 GPCR Weekly News, April 15 to 21, 2024
great conversation about this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
biosensors involves the use of mini-G proteins, which are genetically engineered portions of Gα subunits designed Can the pharmaceutical industry reduce attrition rates? Innovation in the pharmaceutical industry: New estimates of R&D costs. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. Rational design of allosteric modulators: Challenges and successes.
- The Truth About GPCR Product Launches: Years in the Making
Months were spent debating assay design. IP1 isn’t naturally abundant or easy to detect. Eventually, the team landed on a design that could accumulate and detect IP1 in a 384-well format. But the moment we got bench-level data that aligned with our design—it became a breakthrough.” — Dr. David Parker spent years designing rare-earth europium probes. Trinquet’s team designed pHSense to detect that, without microscopy.
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
. ✅ Practical insight into how enzyme activation and inhibition shape drug safety, efficacy, and design The Overlooked Step in Every Discovery Program So what does that mean for discovery scientists designing You’re not just designing for receptor activity—you’re designing for enzyme survival. By mastering the difference, discovery teams can anticipate resistance, tune selectivity, and design Kenakin live for an open Q&A session designed for discovery scientists.
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
cryptic binding sites and why some drugs need hours—not minutes—to equilibrate ✅ A framework for designing Unexpected activity profiles, SAR that breaks your QSAR model, and missed opportunities to design more This has direct implications for: Assay timing and readout design Misclassification of lead candidates Design with Intelligence, Not Assumptions Whether you're aiming to discover PAMs, NAMs, or bias-selective modulators, the principles in this lecture equip you to design ligands that not only bind, but bind
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
cost-effective pharmacokinetic assays Why Intracellular GPCR Drugs Change the Game For decades, drug design You get longer activity with shorter exposure—a dream scenario for drug designers. how this plays out in model systems and clinical data—and why residence time should be a first-class design He also reviews key scaffold properties that determine success, offering practical tips for design teams And while orthosteric ligands may never reach them, properly designed intracellular drugs can.
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
Overcoming them requires careful assay design and strategic use of the right fluorescent probes. : How HCS works and why it is increasingly central to GPCR-based drug discovery The key phases of designing Assay Design and Pilot Optimization Successful HCS begins with a clearly defined biological question (A) After experimental design, wet lab work is performed to acquire high-content cell images, which then At Celtarys, we remain committed to enabling this transition and supporting researchers as they design
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
For drug discovery teams navigating safety margins, biased signaling, and combination therapy design, In this lesson, you’ll learn why this distinction is not just theory, but a practical framework to design This means you can design molecules that potentiate beneficial pathways without shutting down basal signaling The result is not just cleaner assay design but a sharper decision framework for selecting, prioritizing Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters
- Signals in Motion: Pain, Metabolism & Terry’s Corner
receptor theory with today’s most pressing pharmacological questions, from biased signaling to allosteric design Terry’s Corner gives you timeless and timely tools to improve selectivity, model efficacy, and design Upgrade Your Screening Strategy Leadership in Ligand Design – The Celtarys Origin Story In this founder
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
Yet small design choices—often treated as technical details—quietly reshape the affinity you think you Design GPCR binding affinity experiments that tell the truth , ensuring affinity data support—rather in-depth lessons and 3 live AMAs spanning binding, kinetics, efficacy, mechanism, and experimental design—built reflects something deeper than metrics: a shared demand for clearer interpretation, stronger experimental design GPCR Premium Membership Gives You an Edge Premium Membership is designed for scientists and teams who
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
It would later shape how he designed fluorescent probes, how he evaluated biological constraints, and The project required designing peptide–fluorophore conjugates that would bind GLP-1R with high specificity Designing Reliable GPCR Imaging Tools for Real Biological Systems Success brought new challenges. This strategy accelerated discovery and reduced noise, helping them understand how each design change His team is exploring AI-enabled probe design, multiplex fluorescent strategies that allow visualization
- Curve Shifts Don’t Lie, But Your Eyes Might
By the end, you’ll know how to choose the right test, design experiments with power built in, and validate Once you learn to design with power analysis, you’ll never run blind again. Specifically, you’ll be able to: Design experiments with the right replicate count to balance rigor and It’s learning how to design, analyze, and decide with confidence built in. Terry’s Corner is designed to give you the edge.
- The One Reason Why Biotech Startups Fail More Often Than They Should
Instead of adding more work to feel safer, teams start designing fewer experiments with sharper intent slowly fall apart is not confidence or optimism. ✅ It is the presence of someone actively designing Designing order also changes how teams experience pressure. Biotech does not become easy when an order is designed. It becomes survivable. It is about designing clarity early enough that chaos never takes over.
- Your GPCR Program Decisions Depend on Good Data Interpretation
Myth of Multiple Affinity Sites Slows You Down Traditional models that shaped affinity analysis were designed Kenakin shows exactly how to separate what matters from what misleads—practical, real-world expertise designed Ingo Hartung : State-of-the-art design of small molecule drugs, including PROTACs Dr. His leadership principles: Hire for attitude and team fit—not just credentials Design workflows that GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
Whether you’re early in your career or pushing the edge of MoA design, weekly lesson help you apply key Terry Kenakin Terry’s Corner is your space focused on GPCR pharmacology designed just for you. With strong signal stability, HTS compatibility, and broad assay versatility, CELT-419 is designed for
- Understanding Enzyme Inhibition In GPCR Discovery Programs
understanding inhibition to advance GPCR drug discovery This Week’s GPCR Intelligence: Every drug you design Whether you’re designing a ligand, optimizing ADME, or predicting PK, enzyme inhibition defines what This week’s Terry’s Corner reframes inhibition not as background theory—but as a design lens for smarter When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design. Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
. 🔍 This Week in Premium: Sneak Peek A curated preview of this week’s Premium classified content — designed to keep you ahead without noise or delays: Industry insights: Structure-Based Drug Design Summit; AI-Powered Must-read publications: GPCRchimeraDB: Database of engineered GPCR designs. lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—all designed GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
Win on kinetics, not just Kd: Dynamic binding means “affinity” moves—design readouts and decisions that Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters From Bench Frustrations to Breakthrough Design For decades, GPCR trafficking research relied on overexpression It's designed to help GPCR scientists and teams move faster by consolidating scattered updates into a Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
How a Chemical Design Sparked a GPCR Imaging Breakthrough The concept was elegant: antibodies weren’t The design didn't just work — it revealed. Interdisciplinary design isn’t optional in GPCR imaging. strategies for parallel receptor mapping Super-resolution imaging of receptor nanodomains AI-assisted probe design
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
And if your development plan was designed to persuade , not to withstand pressure , then you are not This is the principle of strategic reverse engineering . 👉 It means designing your development path in practice: You align trial endpoints with future label claims , not just scientific curiosity You design your leadership team evaluates options. ✅ Every strategic decision, from indication selection to study design It’s to design smarter , from the very beginning.
- From Snapshots to Predictions: Why Mechanism of Action Matters
insights ✅ Tools to distinguish orthosteric vs. allosteric mechanisms ✅ A framework for using models to design They design experiments. In HIV entry studies, purified gp120 was too expensive for routine assays. predictive insights Differentiate orthosteric vs. allosteric mechanisms with confidence Apply models to design It’s learning how to design, interpret, and decide with models built in . Terry’s Corner is designed to give you the edge.
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
Design for translation: Map sensitivity ranges to tissue contexts so your plate data predicts what happens Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters But behind every “new” assay is a decade of design, failure, and rethinking. Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed
























